Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1395494 | European Journal of Medicinal Chemistry | 2015 | 17 Pages |
•Synthesis of novel marinopyrrole derivatives.•Identified marinopyrroles as selective Mcl-1 or dual Mcl-1/Bcl-xL inhibitors.•Structure activity relationships of novel marinopyrroles bound to Mcl-1.•Marinopyrroles bind to the Mcl-1 BH3 pocket.•Marinopyrroles downregulate Mcl-1 levels and induce apoptosis.
Inhibition of anti-apoptotic Mcl-1 is a promising anticancer strategy to overcome the survival and chemoresistance of a broad spectrum of human cancers. We previously reported on the identification of a natural product marinopyrrole A (1) that induces apoptosis in Mcl-1-dependent cells through Mcl-1 degradation. Here, we report the design and synthesis of novel marinopyrrole-based analogs and their evaluation as selective inhibitors of Mcl-1 as well as dual Mcl-1/Bcl-xL inhibitors. The most selective Mcl-1 antagonists were 34, 36 and 37 with 16-, 13- and 9-fold more selectivity for disrupting Mcl-1/Bim over Bcl-xL/Bim binding, respectively. Among the most potent dual inhibitors is 42 which inhibited Mcl-1/Bim and Bcl-xL/Bim binding 15-fold (IC50 = 600 nM) and 33-fold (500 nM) more potently than (±)-marinopyrrole A (1), respectively. Fluorescence quenching, NMR analysis and molecular docking indicated binding of marinopyrroles to the BH3 binding site of Mcl-1. Several marinopyrroles potently decreased Mcl-1 cellular levels and induced caspase 3 activation in human breast cancer cells. Our studies provide novel “lead” marinopyrroles for further optimization as selective Mcl-1 inhibitors and dual Mcl-1 and Bcl-xL inhibitors.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide